Skip to contentHelp us improve by providing feedback or contacting help@jisc.ac.uk
  • Browse
  • Publish
Sign in with ORCID

kinase inhibitor

Research Topic

Language: English

Sign in for more actions

This is a research topic created to provide authors with a place to attach new problem publications.

Research topics below this in the hierarchy

  • cytokine
  • receptor egfr

Research topics above this in the hierarchy

  • macrophages

Research problems linked to this topic

  • Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) are a response to EGFR-tyrosine kinase inhibitor.
  • Targeted agents for small cell lung cancer (SCLC) include inhibitors of angiogenesis, tyrosine kinase inhibitors and signal transduction pathway inhibitors.
  • Dysregulation and mutations of protein kinases play causal roles in many diseases including cancer.
  • Targeting BCR/ABL by ABL-directed kinase inhibitors (AKIs) induces long lasting remissions in patients with chronic myeloid leukemia (CML), and short remissions in Ph+ acute lymphatic leukemia (ALL).

Octopus

Contact us: help@jisc.ac.uk

Browse

Publish

About

FAQs

Get involved

Terms

Privacy

Accessibility

Cookie Policy

In partnership with

Jisc Logo

With support from

UKRI

A collaboration with

Jisc Logo